Apixaban

Description:

API nomen est scriptor indication specification US DMF EU DMF BOLETUS
Apixaban VTE In Domus,

Product Detail

Product Tags

FRUCTUS SINGULA

Maecenas vitae

Apixaban sit amet electionem selectivam, quod convertitur cum Matrix factor Xa Reg valores 0,08 m 0,17 m, et in hominibus, uenatibus, respectively [I].

X factor, etiam notum est Marcus, eponym Prower elementum est, an enzyme COAGULUM Caesar. X factor est activated, per hydrolysis, elementum in Xa per elementum utrumque IX. Actum est forma factor Xa Xa afferre momenti alternis modus coagulationis factorthrombokinase.Inhibiting Anticoagulation. Xa inhibitors recta sunt anticoagulants vulgaris [II].

Herpesvirus hominis; sistebant enim Apixabanhas summo gradu potentiae, selectivity, et facultas in factor Xa et ex Reg 0,08 m 0,17 m et ad Quantum Materiae Humanum Triticum Triticum Xa et Xa, respectively [I]. Apixaban in multum diei clotting tempore normalis human plasma cum concentratione (EC2x) de 3.6, 0.37, 7.4 et 0.4 μm, quod non requiritur necessario ad duplum sinum prothrombin tempore (TP Allelúia), mutatio prothrombin tempore (MPT) activated parte thromboplastin tempore ( APTT) et HepTest. Praeter, Apixaban ostendit in hominem summa potentia, uenatibus plasma: minus autem potentia, canis rat, et in utroque plasma ad PT, & APTT assays [III].

In vivo: Apixaban exihibited Farmacocinética est optimum in ipso humilis saepe alvi deiectio (Cl: 0.02 L-I kg-1h), et humilis volumine distributionis (Vdss: 0,2 L / kg) in canem. Praeter, et ostendit Apixaban dimidium-vita moderatus et T1 / II horas in 5,8 oris bioavailability et bonum (F: LVIII%) [I]. In arteriovenous, shunt thrombosis (AVST), venarum thrombosis (MN) et electrically mediata surculi tenerrimi, arteriarum thrombosis (ECat) lepus exempla monstrabit, Apixaban produci antithrombotic effectus est EC50 de CCLXX NM, CX NM, LXX m in pondere-dependens modo [III ]. Apixaban significantly inhibuit Xa actio factor 0,22 cum autem IC50 μm in lepus ex vivo [IV]. In chimpanzee, Apixaban etiam ostendit de parva volumine distribution (Vdss: I kg-L 0,17), saepe alvi deiectio humilis systemica (Cl: 1h 0.018 kg-L-I), et bene oris bioavailability (F: LIX%) [V].

Re:
Plato DJP, Orwat John Koch S, et al. Inventio est 1- (IV-methoxyphenyl) -7-oxo 6 (4 (I-II-y-oxopiperidin) phenyl) 4, V, VI, VII, I-II, tetrahydro pyrazolo [III, 4 c] pyridine-III-sciureus (Apixaban, BMS, (DLXII)CCXLVII), est summe potens, electionem selectivam, efficax et viva voce bioavailable inhibitor sanguinem COAGULUM factor Xa [J]. Journal medicinalium liber, MMVII, L (XXII) 5339-5356.
S. P Sidhu Direct factor Xa Inhibitors ut anticoagulants [J].
Wong PC, J. Crain, Xin B, et al. Apixaban, in oris, et laudábilis nimis electionem selectivam recta elementum Xa precursor: in vitro diffunduntur, et antithrombotic antihemostaticstudies [J]. Journal de thrombosis et Haemostasis, MMVIII, VI (V): 820-829.
Zhang D, et K, N Raghavan, et al. Metabolism, Farmacocinética Pharmacodynamics et elementum et, cuniculosae Celtiberiae Xa precursor apixaban [J]. Journal de thrombosis et StomaphyX, MMX, XXIX (I): 70-80.
Ipse K, Luettgen definition | JM Zhang D, et al. Preclinical Farmacocinética et Pharmacodynamics apixaban autem: potens est enim precursor Xa et electionem selectivam factor [J]. Acta medicamento metabolism quod Farmacocinética, MMXI, XXXVI (III): 129-139.

Apixaban sit amet electionem selectivam, quod convertitur cum Matrix factor Xa Reg valores 0,08 m 0,17 m, et in hominibus, uenatibus, respectively [I].

X factor, etiam notum est Marcus, eponym Prower elementum est, an enzyme COAGULUM Caesar. X factor est activated, per hydrolysis, elementum in Xa per elementum utrumque IX. Actum est forma factor Xa Xa afferre momenti alternis modus coagulationis factorthrombokinase.Inhibiting Anticoagulation. Xa inhibitors recta sunt anticoagulants vulgaris [II].

Herpesvirus hominis; sistebant enim Apixabanhas summo gradu potentiae, selectivity, et facultas in factor Xa et ex Reg 0,08 m 0,17 m et ad Quantum Materiae Humanum Triticum Triticum Xa et Xa, respectively [I]. Apixaban in multum diei clotting tempore normalis human plasma cum concentratione (EC2x) de 3.6, 0.37, 7.4 et 0.4 μm, quod non requiritur necessario ad duplum sinum prothrombin tempore (TP Allelúia), mutatio prothrombin tempore (MPT) activated parte thromboplastin tempore ( APTT) et HepTest. Praeter, Apixaban ostendit in hominem summa potentia, uenatibus plasma: minus autem potentia, canis rat, et in utroque plasma ad PT, & APTT assays [III].

In vivo: Apixaban exihibited Farmacocinética est optimum in ipso humilis saepe alvi deiectio (Cl: 0.02 L-I kg-1h), et humilis volumine distributionis (Vdss: 0,2 L / kg) in canem. Praeter, et ostendit Apixaban dimidium-vita moderatus et T1 / II horas in 5,8 oris bioavailability et bonum (F: LVIII%) [I]. In arteriovenous, shunt thrombosis (AVST), venarum thrombosis (MN) et electrically mediata surculi tenerrimi, arteriarum thrombosis (ECat) lepus exempla monstrabit, Apixaban produci antithrombotic effectus est EC50 de CCLXX NM, CX NM, LXX m in pondere-dependens modo [III ]. Apixaban significantly inhibuit Xa actio factor 0,22 cum autem IC50 μm in lepus ex vivo [IV]. In chimpanzee, Apixaban etiam ostendit de parva volumine distribution (Vdss: I kg-L 0,17), saepe alvi deiectio humilis systemica (Cl: 1h 0.018 kg-L-I), et bene oris bioavailability (F: LIX%) [V].

Re:
Plato DJP, Orwat John Koch S, et al. Inventio est 1- (IV-methoxyphenyl) -7-oxo 6 (4 (I-II-y-oxopiperidin) phenyl) 4, V, VI, VII, I-II, tetrahydro pyrazolo [III, 4 c] pyridine-III-sciureus (Apixaban, BMS, (DLXII)CCXLVII), est summe potens, electionem selectivam, efficax et viva voce bioavailable inhibitor sanguinem COAGULUM factor Xa [J]. Journal medicinalium liber, MMVII, L (XXII) 5339-5356.
S. P Sidhu Direct factor Xa Inhibitors ut anticoagulants [J].
Wong PC, J. Crain, Xin B, et al. Apixaban, in oris, et laudábilis nimis electionem selectivam recta elementum Xa precursor: in vitro diffunduntur, et antithrombotic antihemostaticstudies [J]. Journal de thrombosis et Haemostasis, MMVIII, VI (V): 820-829.
Zhang D, et K, N Raghavan, et al. Metabolism, Farmacocinética Pharmacodynamics et elementum et, cuniculosae Celtiberiae Xa precursor apixaban [J]. Journal de thrombosis et StomaphyX, MMX, XXIX (I): 70-80.
Ipse K, Luettgen definition | JM Zhang D, et al. Preclinical Farmacocinética et Pharmacodynamics apixaban autem: potens est enim precursor Xa et electionem selectivam factor [J]. Acta medicamento metabolism quod Farmacocinética, MMXI, XXXVI (III): 129-139.

eget compages

Apixaban

CERTIFICATE

2018 GMP-2
原料药GMP证书201811(captopril ,thalidomide etc)
GMP-of-PMDA-in-Chanyoo-平成28年08月03日 Nantong-Chanyoo-Pharmatech-Co
FDA-EIR-Letter-201901

QUALITY MANAGEMENT

Quality management1

rogationem 18 Aestimatio qualis Constantia quae probatus projects 4, et 6 projects sub consilio.

Quality management2

Qualis international venditio procuratio ratio provecta iam posuit fundamentum.

Quality management3

Qualis vigilantia fugit per totum vitae cursum ad curare quale productum est ac medicinales effectus. 

Quality management4

Demandis regulatory Negotiis professio bigas species sustinet et adnotatione durante application.

PROLATIO MAGISTERIUM

cpf5
cpf6

Korea Countec packaging linea Bottled

cpf7
cpf8

Taiwan CVC packaging linea Bottled

cpf9
cpf10

CAM packaging linea Italia Board

cpf11

Fette artans German Apparatus

cpf12

Iaponia Viswill Traba Detector

cpf14-1

Des Control Room

SOCIUS

internationalis cooperante
International cooperation
domesticis cooperante
Domestic cooperation

  • priorem:
  • Deinde:

  • Dimitte nobis scribere Read more